European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Wednesday Trading
European equities traded in the US as American depositary receipts were moving sharply lower Wednesday morning, falling 1.39% to 1,402.95 on the S&P Europe Select ADR Index. Gainers in continental Eur
Evaxion Biotech | 6-K: Report of foreign private issuer (related to financial reporting)
Evaxion Biotech A/S — Existing cash and cash equivalents are expected to be sufficient to fund operating expenses and capital expenditure requirements for the first quarter of 2025
Evaxion Biotech A/S — Existing cash and cash equivalents are expected to be sufficient to fund operating expenses and capital expenditure requirements for the first quarter of 2025
Evaxion Biotech Cash Position as of March 31 Was $11.7M >EVAX
Evaxion Biotech Cash Position as of March 31 Was $11.7M >EVAX
Express News | Evaxion Biotech A/S - Expects Existing Cash and Cash Equivalents Will Be Sufficient to Fund Its Oper Expenses and Capex Requirements Into Q1 2025
Evaxion Biotech's net revenue for the first quarter was $1.194 million
Evaxion Biotech's net revenue for the first quarter was $1.194 million
Express News | Evaxion Biotech Q1 Net Income USD 1.194 Million
Express News | Evaxion Biotech Q1 Operating Income USD -4.396 Million
Express News | Evaxion Biotech Q1 Basic EPS USD 0.03
Express News | Evaxion Biotech Q1 Pretax Profit USD 976 Thousand
Evaxion Biotech 1Q Rev $51,000 >EVAX
Evaxion Biotech 1Q Rev $51,000 >EVAX
Evaxion Announces Business Update and First Quarter 2024 Financial Results
Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, provides business update and announces first quarter 2024 financial results.
Evaxion Biotech Adjusts Series A Warrant Terms
European Equities Traded in the US as American Depositary Receipts Trend Higher Friday, End Week Marginally Lower
European equities traded in the US as American depositary receipts were moving higher Friday morning, rising 0.63% to 1,424.72 on the S&P Europe Select ADR Index. However, the gain likely won't be eno
Evaxion Biotech Plans to Unveil 'Positive' Data From Phase 2 Study of Advanced Melanoma Combination Treatment
Evaxion Biotech (EVAX) said late Thursday it plans to present "positive" immune data from a phase 2 study assessing its personalized cancer vaccine EVX-01 combined with anti-PD1 therapy in patients wi
Evaxion Biotech's Vaccine Shows Promise in Phase 2
Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading
Tech stocks led European equities traded in the US as American depositary receipts modestly higher Thursday morning, rising 0.4% to 1,428.1 on the S&P Europe Select ADR Index. From continental Europe,
Evaxion to Present New Positive Data From Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024
Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, today announces its participation in the American Society of Clinical Oncology (ASCO) Annual Meeting, where it will present positive immune data form its ongoing EVX-01 Phase 2 study.
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading
European equities traded in the US as American depositary receipts fell Wednesday morning, declining 0.48% to 1,423.09 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading
European equities traded in the US as American depositary receipts were trending modestly higher late Tuesday morning, rising 0.32% to 1,431.33 on the S&P Europe Select ADR Index. From continental Eur